Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.70 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 6/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.37 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2159593 | 0.93 | FAAH (0.73) | FAAHMAPTPLA2G2AL3MBTL1TP53 | |
| SCHEMBL2167660 | 0.93 | FAAH (0.81) | FAAHRECQLTHRBPLA2G2ACNR1 | |
| SCHEMBL2168480 | 0.91 | FAAH (0.64) | FAAHMAPTPLA2G2ALMNATP53 | |
| SCHEMBL2160399 | 0.91 | FAAH (0.71) | FAAHRECQLMAPTPLA2G2APTGDR2 | |
| SCHEMBL2159918 | 0.90 | FAAH (0.85) | FAAHMAPTPLA2G2ALMNATP53 | |
| SCHEMBL2168840 | 0.90 | FAAH (0.62) | FAAHMAPTTHRBTP53 | |
| SCHEMBL2227880 | 0.90 | FAAH (0.68) | FAAHRECQLMAPTTHRBCNR1 | |
| SCHEMBL9952414 | 0.89 | FAAH (0.64) | FAAHRECQLMAPTTHRBMET | |
| SCHEMBL2168877 | 0.89 | FAAH (0.82) | FAAHMAPTPLA2G2ALMNATP53 | |
| SCHEMBL2170453 | 0.88 | FAAH (0.79) | FAAHMAPTTHRBPLA2G2ACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8884020-B2 | Indole compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-11-11 | — | — | US | claimed |
| US-20130224151-A1 | Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain | UNITED STATES OF AMERICA (US) | 2013-08-29 | — | — | US | claimed |
| EP-2610244-A1 | Indole compounds | Ironwood Pharmaceuticals, Inc. (US) | 2013-07-03 | — | — | EP | claimed |
| US-20130150346-A1 | Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome | QUEST VENTURES LTD. (GB) | 2013-06-13 | — | — | US | claimed |
| WO-2011123719-A2 | USE OF FAAH INHIBITORS FOR TREATING ABDOMINAL, VISCERAL AND PELVIC PAIN | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | WO | claimed |
| WO-2011085216-A2 | USE OF FAAH INHIBITORS FOR TREATING PARKINSON'S DISEASE AND RESTLESS LEGS SYNDROME | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | WO | claimed |
| US-20100197708-A1 | INDOLE COMPOUNDS | WELLS FARGO BANK, NATIONAL ASSOCIATION | 2010-08-05 | — | — | US | claimed |
| US-20090118503-A1 | FAAH INHIBITORS | IRONWOOD PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | claimed |
| US-20130224151-A1 | Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain | UNITED STATES OF AMERICA (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130150346-A1 | Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome | QUEST VENTURES LTD. (GB) | 2013-06-13 | — | — | US | disclosed |
| WO-2011123719-A2 | USE OF FAAH INHIBITORS FOR TREATING ABDOMINAL, VISCERAL AND PELVIC PAIN | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130224151-A1 | Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain | FAAH, FAAH2, PNLIP | FAAH 1/4885RECQL 2286/4885MAPT 4229/4885 |
| US-20100197708-A1 | INDOLE COMPOUNDS | IDO1, IDO2, TPH2 | FAAH 109/4885RECQL 4469/4885MAPT 997/4885 |
| US-20090118503-A1 | FAAH INHIBITORS | FAAH, FAAH2, CNR2 | FAAH 1/4885RECQL 4194/4885MAPT 2737/4885 |
| US-20130150346-A1 | Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome | FAAH, FAAH2, MGLL | FAAH 1/4885RECQL 417/4885MAPT 3165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.